Payment overview · 2025
General Payments
$760.22
37 reported records · 12 companies
Healthcare provider profile · identity verified
Joseph A Kowalczyk, MD
Allopathic & Osteopathic Physicians|Internal Medicine · OAK LAWN, IL · NPI 1831166255
Verified facts
What the public records show
CMS Open Payments records show Joseph A Kowalczyk, MD received $760.22 in general payments during 2025 across 37 reported records.
PFIZER INC. accounted for 22.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro, Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 255 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 528 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $174.36 | 22.9% | 9 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $118.30 | 15.6% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $95.50 | 12.6% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $95.40 | 12.6% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $70.89 | 9.3% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $44.69 | 5.9% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $38.38 | 5.0% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $34.05 | 4.5% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $26.99 | 3.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $22.36 | 2.9% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $20.58 | 2.7% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.72 | 2.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $760.22 | 37 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $125.10 | 7 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $125.10 | 7 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $70.89 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $60.78 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $58.02 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $56.95 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $49.26 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $49.26 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $49.26 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $44.69 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $42.62 | 2 | 2025 |
Source payment records
|
|||||
| VOWST Normalized: vowst |
Biological | Aimmune Therapeutics, Inc. | $38.38 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $37.38 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $37.38 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $34.72 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $34.05 | 2 | 2025 |
Source payment records
|
|||||
| PROCLAIM Normalized: proclaim |
Device | Abbott Laboratories | $26.99 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $22.36 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $20.58 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $18.73 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $18.72 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $16.56 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 528 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 50 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 255 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 74 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
255 | 41 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
74 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
528 | 75 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1201 | 240 |
| Amlodipine Besylate | Amlodipine Besylate | 1040 | 172 |
| Levothyroxine Sodium | Levothyroxine Sodium | 921 | 113 |
| Furosemide | Furosemide | 714 | 135 |
| Metoprolol Succinate | Metoprolol Succinate | 616 | 127 |
| Potassium Chloride | Potassium Chloride | 604 | 70 |
| Lisinopril | Lisinopril | 551 | 111 |
| Carvedilol | Carvedilol | 550 | 88 |
| Metformin Hcl | Metformin Hcl | 540 | 92 |
| Eliquis | Apixaban | 528 | 75 |
| Gabapentin | Gabapentin | 496 | 80 |
| Losartan Potassium | Losartan Potassium | 487 | 118 |
| Pantoprazole Sodium | Pantoprazole Sodium | 450 | 101 |
| Escitalopram Oxalate | Escitalopram Oxalate | 419 | 65 |
| Tamsulosin Hcl | Tamsulosin Hcl | 416 | 85 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 406 | 114 |
| Omeprazole | Omeprazole | 372 | 69 |
| Metoprolol Tartrate | Metoprolol Tartrate | 348 | 62 |
| Clopidogrel | Clopidogrel Bisulfate | 337 | 28 |
| Hydralazine Hcl | Hydralazine Hcl | 335 | 57 |
| Mirtazapine | Mirtazapine | 335 | 35 |
| Simvastatin | Simvastatin | 318 | 52 |
| Hydrochlorothiazide | Hydrochlorothiazide | 261 | 54 |
| Jardiance | Empagliflozin | 255 | 41 |
| Allopurinol | Allopurinol | 240 | 44 |
| Tramadol Hcl | Tramadol Hcl | 209 | 60 |
| Trazodone Hcl | Trazodone Hcl | 207 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 196 | 15 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 182 | 76 |
| Sertraline Hcl | Sertraline Hcl | 170 | 25 |
| Famotidine | Famotidine | 166 | 18 |
| Alprazolam | Alprazolam | 164 | 38 |
| Midodrine Hcl | Midodrine Hcl | 164 | 16 |
| Donepezil Hcl | Donepezil Hcl | 161 | 35 |
| Montelukast Sodium | Montelukast Sodium | 159 | 18 |
| Memantine Hcl | Memantine Hcl | 157 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 148 | 30 |
| Xarelto | Rivaroxaban | 148 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 141 | 13 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 140 | 17 |
| Nifedipine Er | Nifedipine | 138 | 17 |
| Spironolactone | Spironolactone | 137 | 30 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 128 | 40 |
| Levetiracetam | Levetiracetam | 115 | 11 |
| Digoxin | Digoxin | 114 | suppressed |
| Finasteride | Finasteride | 111 | 32 |
| Warfarin Sodium | Warfarin Sodium | 110 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 107 | 23 |
| Celecoxib | Celecoxib | 106 | 26 |
| Amiodarone Hcl | Amiodarone Hcl | 105 | 26 |
| Meloxicam | Meloxicam | 104 | 24 |
| Metformin Hcl Er | Metformin Hcl | 103 | 29 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 103 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 98 | 35 |
| Clonidine Hcl | Clonidine Hcl | 96 | suppressed |
| Baclofen | Baclofen | 95 | suppressed |
| Glimepiride | Glimepiride | 94 | 29 |
| Lorazepam | Lorazepam | 94 | 27 |
| Torsemide | Torsemide | 89 | 28 |
| Cephalexin | Cephalexin | 88 | 65 |
| Fluoxetine Hcl | Fluoxetine Hcl | 83 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 82 | 39 |
| Prednisone | Prednisone | 80 | 45 |
| Azithromycin | Azithromycin | 75 | 64 |
| Labetalol Hcl | Labetalol Hcl | 74 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 74 | 24 |
| Ozempic | Semaglutide | 74 | 11 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 71 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 71 | 21 |
| Methenamine Hippurate | Methenamine Hippurate | 70 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 69 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 66 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 66 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 64 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 62 | 40 |
| Enalapril Maleate | Enalapril Maleate | 58 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 57 | suppressed |
| Atenolol | Atenolol | 56 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 54 | 17 |
| Mesalamine | Mesalamine | 52 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 52 | 16 |
| Bethanechol Chloride | Bethanechol Chloride | 51 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 50 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 48 | 19 |
| Valsartan | Valsartan | 45 | suppressed |
| Irbesartan | Irbesartan | 44 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 44 | 11 |
| Nystatin | Nystatin | 43 | 24 |
| Morphine Sulfate | Morphine Sulfate | 42 | suppressed |
| Synthroid | Levothyroxine Sodium | 42 | 11 |
| Lovastatin | Lovastatin | 40 | suppressed |
| Diazepam | Diazepam | 38 | suppressed |
| Olanzapine | Olanzapine | 38 | suppressed |
| Ursodiol | Ursodiol | 38 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 37 | 12 |
| Glipizide | Glipizide | 37 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 37 | 17 |
| Sucralfate | Sucralfate | 36 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 34 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 34 | 27 |
| Amoxicillin | Amoxicillin | 33 | 24 |
| Bupropion Hcl Sr | Bupropion Hcl | 33 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 33 | 23 |
| Lidocaine | Lidocaine | 33 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 33 | suppressed |
| Ezetimibe | Ezetimibe | 32 | 11 |
| Bumetanide | Bumetanide | 31 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 31 | 17 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 30 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 29 | 13 |
| Cevimeline Hcl | Cevimeline Hcl | 28 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 28 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 28 | 13 |
| Fenofibrate | Fenofibrate Nanocrystallized | 28 | suppressed |
| Latanoprost | Latanoprost | 28 | suppressed |
| Clonazepam | Clonazepam | 27 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 27 | suppressed |
| Pregabalin | Pregabalin | 27 | suppressed |
| Chlorthalidone | Chlorthalidone | 26 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 26 | suppressed |
| Januvia | Sitagliptin Phosphate | 26 | suppressed |
| Glipizide Er | Glipizide | 25 | suppressed |
| Lamotrigine | Lamotrigine | 25 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 24 | 16 |
| Myrbetriq | Mirabegron | 24 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 23 | 18 |
| Divalproex Sodium | Divalproex Sodium | 23 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 23 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 23 | suppressed |
| Metronidazole | Metronidazole | 23 | 20 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 23 | suppressed |
| Risperidone | Risperidone | 23 | suppressed |
| Naproxen | Naproxen | 22 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Clonidine | Clonidine | 20 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 20 | suppressed |
| Mupirocin | Mupirocin | 20 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 20 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 20 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 19 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | suppressed |
| Fluconazole | Fluconazole | 19 | 16 |
| Mounjaro | Tirzepatide | 19 | suppressed |
| Temazepam | Temazepam | 19 | suppressed |
| Bupropion Xl | Bupropion Hcl | 18 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 18 | suppressed |
| Ibuprofen | Ibuprofen | 18 | 11 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 18 | 18 |
| Pioglitazone Hcl | Pioglitazone Hcl | 18 | suppressed |
| Renacidin | Citric Ac/Gluconolact/Mag Carb | 18 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Lactulose | Lactulose | 17 | suppressed |
| Tradjenta | Linagliptin | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Klor-Con M20 | Potassium Chloride | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 14 | suppressed |
| Humulin N Kwikpen | Insulin Nph Human Isophane | 14 | suppressed |
| Methotrexate | Methotrexate Sodium | 14 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 14 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 14 | suppressed |
| Amantadine | Amantadine Hcl | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | suppressed |
| Nystop | Nystatin | 13 | 11 |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 13 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Dexamethasone | Dexamethasone | 11 | suppressed |
| Humulin R | Insulin Regular, Human | 11 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 11 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 11 | suppressed |
| Novolog | Insulin Aspart | 11 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $760.22 · 37 records | PFIZER INC. | ABRYSVO, AIRSUPRA, BREZTRI, COMIRNATY, Cologuard Collection Kit, ELIQUIS, FARXIGA, GVOKE HYPOPEN, JARDIANCE, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, PROCLAIM, REPATHA, REXULTI, TRELEGY ELLIPTA, VOWST, Wegovy, ZEPBOUND, ZORYVE | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error